Patents Assigned to Amgen British Columbia Inc.
  • Anti-GCC antibody molecules and related compositions and methods
    Patent number: 10941211
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 9, 2021
    Assignees: MILLENNIUM PHARMACEUTICALS, INC., AMGEN BRITISH COLUMBIA INC.
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20180355062
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: July 6, 2018
    Publication date: December 13, 2018
    Applicants: Millennium Pharmaceuticals, Inc., Amgen British Columbia Inc.
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin